Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 10, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 14.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 10, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 15, 2027 | Atacicept in Multiple Glomerular Diseases | Trial Milestone | Phase 2 |
| May 21, 2031 | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept | Trial Milestone | Phase 2 |
Track VERA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open VERA in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.